<DOC>
	<DOCNO>NCT01358240</DOCNO>
	<brief_summary>This study safety efficacy Econazole Nitrate Foam 1 % Foam Vehicle subject interdigital tinea pedis ( athlete 's foot toe ) . This 6 week study 4 week treatment period 2 week follow-up evaluation . The study also utilize Econazole Nitrate Cream 1 % ( safety comparison ) Placebo cream blinding purpose .</brief_summary>
	<brief_title>Safety Efficacy Econazole Nitrate Foam 1 % Foam Vehicle Subjects With Tinea Pedis</brief_title>
	<detailed_description />
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<mesh_term>Econazole</mesh_term>
	<criteria>Be least 12 year age either sex . Have clinical diagnosis interdigital tinea pedis involve least 2 web space total extends approximately 1 inch proximal web space metatarsophalangeal joint least ) moderate scale ii ) mild erythema define Grade 2 Grade 1 , respectively Grading Signs Symptoms ( Section 10.1 ) baseline . Be willing able give inform consent/assent parent/guardian , applicable . Be willing able use assign study medication direct commit followup visit duration study . Have microscopic evidence ( positive KOH ) presence fungi . Evaluable subject must positive KOH fungal culture positive dermatophyte skin scraping take Baseline Visit . Subjects positive KOH may enter study pending result fungal culture . Be good health free disease physical condition might , Investigator 's opinion , expose subject unacceptable risk study participation . Females must nonpregnant ( confirm negative urine pregnancy test ( UPT ) baseline ) , nonlactating intend become pregnant course study . Is pregnant nurse planning pregnancy study . Has use topical antifungal topical corticosteroid foot within 30 day prior start study . Has receive systemic antifungal therapy within 12 week prior start study medication . Has use systemic antibacterial systemic corticosteroid within 30 day prior start study . Systemic corticosteroid include intranasal , inhale , ophthalmic corticosteroid use management allergy , pulmonary disorder condition . Has history uncontrolled diabetes mellitus immunocompromised ( due disease , e.g. , HIV , medication ) . Has concurrent tinea infection e.g . tinea versicolor , tinea cruris , moccasintype tinea pedis , etc . ( opinion Investigator ) . Onychomycosis , involve â‰¥ 20 % area either great toenail involvement five toenail total . Has skin disease might interfere evaluation tinea pedis . Is currently enrol investigational drug device study . Has receive investigational drug treatment investigational device within 30 day prior enter study . Is unreliable , include subject history drug alcohol abuse . Has know hypersensitivity component study medication .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Econazole Nitrate</keyword>
	<keyword>Foam</keyword>
	<keyword>Quinnova</keyword>
	<keyword>Tinea Pedis</keyword>
</DOC>